Adverum Biotechnologies Inc (NAS:ADVM)

$ 8.75 -0.18 (-2.02%) Market Cap: 181.62 Mil Enterprise Value: 163.87 Mil PE Ratio: 0 PB Ratio: 1.00 GF Score: 50/100

Adverum Biotechnologies Inc To discuss the preliminary safety and efficacy data Transcript
Feb 08, 2024
Adverum Biotechnologies Inc at HC Wainwright Ophthalmology Virtual Conference Transcript
Aug 16, 2023
Adverum Biotechnologies Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Adverum Biotechnologies Inc ADVM-022 Update Call Transcript
Jul 22, 2021
Q4 2020 Adverum Biotechnologies Inc Earnings Call Transcript
Mar 01, 2021

$133.2 (+3.82%)

Earnings
Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Adverum Biotechnologies Inc Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call Transcript
Nov 14, 2020
Q2 2020 Adverum Biotechnologies Inc Earnings Call Transcript
Aug 10, 2020

$187 (+1.30%)

Earnings
Adverum Biotechnologies Inc Annual Shareholders Meeting Transcript
Jun 23, 2020
Adverum Biotechnologies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Q1 2020 Adverum Biotechnologies Inc Earnings Call Transcript
May 28, 2020

$203.2 (-3.33%)

Earnings
Adverum Biotechnologies Inc to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD Call Transcript
May 04, 2020
Q4 2019 Adverum Biotechnologies Inc Earnings Call Transcript
Mar 12, 2020

$79.8 (-13.82%)

Earnings
Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call Transcript
Feb 09, 2020
Adverum Biotechnologies Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Q3 2019 Adverum Biotechnologies Inc Earnings Call Transcript
Nov 07, 2019

$81.4 (+1.75%)

Earnings
Adverum Biotechnologies Inc Key Opinion Leader Discussion of Additional Cohort 1 Data from the Phase 1 OPTIC Trial Transcript
Oct 12, 2019
Adverum Biotechnologies Inc to Review Data Presented at Retina Society 2019 Conference Call Transcript
Sep 12, 2019
Q2 2019 Adverum Biotechnologies Inc Earnings Call Transcript
Aug 08, 2019

$123.2 (+5.21%)

Earnings

Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call Transcript

Feb 09, 2020 / 03:00PM GMT

Transcript 8-K

Leone D. Patterson

Adverum Biotechnologies, Inc. - President, CEO & Director

Okay, good morning, everyone. I'm Leone Patterson, the Chief Executive Officer of Adverum. And thank you, everybody, for joining me today, who's in the room. We also have people via webcast.

And we've got 90 minutes of time here for this meeting, and I'll make my comments brief because you obviously want to get to our panel discussion and obviously the presentation. Just some housekeeping: You can find the presentation that we'll have today on our website. And then also further -- there will be some forward-looking statements today, and these are disclaimers associated with those.

So getting to the agenda for the day, I wanted to just welcome our 3 prominent retinal specialists who are in the front of the room here: Dr. Khanani, Dr. Boyer and Dr. Kiss. And today, we're going to go through a few areas of importance as it relates to ADVM-022. First of all, we'll have Dr. Kiss go through the preclinical data, but also he will cover the unmet need for wet AMD. And then we're going to have Dr. Boyer, who

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.